IDiyas

For the Inventor, By the Inventor

Racine, WI, United States of America

Richard A Craig

USPTO Granted Patents = 14

Average Co-Inventor Count = 5.1

ph-index = 5

Forward Citations = 172(Granted Patents)


Company Filing History:

goldMedal14 out of 4,177 
 
Abbott Laboratories Corporation
 patents

Years Active: 1992-2006

Loading Chart...
14 patents (USPTO):Explore Patents
1. 7030262 - 3-Amino-2-hydroxyalkanoic acids and their prodrugs (2006-04-18),
2. 6887863 - Hydrazide and alkoxyamide angiogenesis inhibitors (2005-05-03),
3. 6849757 - Antiangiogenic drug to treat cancer, arthritis and retinopathy (2005-02-01),
4. 6632961 - Antiangiogenic drug to treat cancer, arthritis and retinopathy (2003-10-14),
5. 6323228 - 3-substituted indole angiogenesis inhibitors (2001-11-27),
6. 6288261 - Inhibitors of matrix metalloproteinases (2001-09-11),
7. 6242494 - Substituted &bgr;-amino acid inhibitors of methionine aminopeptidase-2 (2001-06-05),
8. 5863946 - Iminoxyderivatives of fenamates as inhibitors of prostaglandin (1999-01-26),
9. 5843968 - Symmetrical bis-heteroarylmethoxy-phenylalkyl carboxylates as inhibitors (1998-12-01),
10. 5795900 - Symmetrical bis-heteroaryl-methoxy-phenylalkyl carboxylates as (1998-08-18),
11. 5756531 - Iminoxy derivatives of indole and indene compounds as inhibitors of (1998-05-26),
12. 5616596 - Substituted arylalkynyl-and heteroarylalkynl-N-hydroxyurea inhibitors of (1997-04-01),
13. 5506261 - Substituted aryl- and heteroarylalkenyl-N-hydroxyurea inhibitors of (1996-04-09),
14. 5169854 - N-substituted-furylalkenyl hydroxamic acid and N-hydroxyurea compounds (1992-12-08),

Title: Celebrating the Innovations of Richard A. Craig

Introduction

Richard A. Craig is a prominent inventor based in Racine, Wisconsin, known for his significant contributions to the field of pharmaceuticals and biotechnology. With an impressive portfolio of 14 patents, Craig has focused his efforts on the development of compounds that target various medical conditions, particularly those associated with angiogenesis.

Latest Patents

Among his latest innovations are two notable patents: the development of 3-Amino-2-hydroxyalkanoic acids and their prodrugs, which are designed to treat conditions arising from or exacerbated by angiogenesis. These compounds are integral to pharmaceutical compositions aimed at inhibiting angiogenesis and treating cancer. Additionally, Craig has patented hydrazide and alkoxyamide compounds that serve as methionine aminopeptidase type 2 (MetAP2) inhibitors, proving beneficial in the inhibition of angiogenesis.

Career Highlights

Richard A. Craig is affiliated with Abbott Laboratories Corporation, where he applies his expertise in medicinal chemistry and pharmaceutical research. His work there contributes to advancing therapeutic solutions that enhance patient care and combat serious health conditions related to blood vessel formation.

Collaborations

Collaboration plays a crucial role in Craig's innovative journey. He has worked alongside notable colleagues such as Andrew O. Stewart and Megumi Kawai, fostering a productive environment that encourages the exchange of ideas and the pursuit of groundbreaking technologies.

Conclusion

Richard A. Craig's dedication to innovation, particularly in the realm of angiogenesis-related treatments, exemplifies the impact of dedicated inventors in the healthcare industry. With ongoing contributions through his patents, Craig continues to pave the way for significant advancements in medical science, highlighting the importance of research and collaboration in developing effective therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…